Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax

19 Dec 2023

Abstract excerpt

ABSTRACT: Hypomethylating agents (HMAs) and venetoclax (Ven) represent the standard of care for patients with acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy. However, the European LeukemiaNet (ELN) risk classifications have been validated for patients treated with intensive therapy. In this study, we validate a recently proposed new molecular prognostic risk signature (mPRS) for...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Hemoglobinopathies and Related Disorders
Share to Myeloproliferative Neoplasms: Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38113472
DOI: 10.1182/bloodadvances.2023011757

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclaxPMID 38113472Read ↗

The prognostic significance of genetics in acute myeloid leukemia under venetoclax-based treatment.Semantic proximity Read ↗

Mayo Genetic Risk Models for Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax + Hypomethylating AgentSemantic proximity Read ↗

Refined ELN 2024 risk stratification improves survival prognostication following venetoclax-based therapy in AML.Semantic proximity Read ↗

Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia: Genotype signatures for response and survival among 301 consecutive patients.Semantic proximity Read ↗

Prognostic Model Combining Mutational and Cytogenetic Profiles in Acute Myeloid Leukemia Treated with Venetoclax and Hypomethylating Agents.Semantic proximity Read ↗

Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine.Semantic proximity Read ↗

Risk stratification of low-dose cytarabine and venetoclax in patients with AML ineligible for intensive chemotherapy.Semantic proximity Read ↗

Venetoclax-based therapy versus hypomethylating agents alone in unfit patients with newly diagnosed acute myeloid leukemia: a real-world study from the PETHEMA registrySemantic proximity Read ↗

A Real-World Evaluation of Frontline Treatment for Acute Myeloid Leukemia With Azacitidine Plus VenetoclaxSemantic proximity Read ↗

Recent advances in targeted therapies in acute myeloid leukemia.Semantic proximity Read ↗

Relapse and resistance in acute myeloid leukemia post venetoclax: improving second lines therapy and combinations.Semantic proximity Read ↗

Building on Foundations: Venetoclax-Based Combinations in the Treatment of Acute Myeloid LeukemiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.